Understanding how the Epstein Barr Virus controls its gene expression during latency
Regulation of Viral Chromatin Architecture During EBV Latency
This study looks at how certain changes in our cells can affect the Epstein Barr Virus while it's resting, helping us understand how it might play a role in diseases like Burkitt lymphoma, which could lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11137629 on NIH RePORTER |
What this research studies
This research investigates the role of epigenetics in regulating the Epstein Barr Virus (EBV) during its latent phase. It focuses on how changes in the 3D structure of chromatin and specific histone modifications influence the virus's gene expression. By exploring the cellular signals that trigger these epigenetic changes, the study aims to uncover the mechanisms that link metabolism to viral gene regulation. Patients may benefit from insights into how EBV contributes to conditions like Burkitt lymphoma and other B-cell malignancies.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with EBV infections or those diagnosed with EBV-associated cancers such as Burkitt lymphoma.
Not a fit: Patients without EBV infections or those not affected by EBV-related cancers may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating EBV-related cancers.
How similar studies have performed: Previous research has shown promising results in understanding the role of epigenetics in viral latency, indicating that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Tempera, Italo — Wistar Institute
- Study coordinator: Tempera, Italo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.